{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T18:11:14Z","timestamp":1792606274557,"version":"4.5.0"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T00:00:00Z","timestamp":1738108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>A considerable number of patients with chronic inflammatory bowel diseases (IBD) are required to manage extensive polypharmaceutical regimes, which significantly elevates the risk of drug\u2013drug interactions. Also, the disease\u2019s impact often leads to the consumption of additional self-medication by the patients such as naturopathic remedies to alleviate disease-induced suffering and nutritional supplements to compensate for malabsorption syndromes inherent to the condition. There is a well-established consensus that polymedication coupled with unregulated supplementary intake can jeopardize the safety of drug therapy. Despite this, pharmaceutical co-supervision\u2014proven to mitigate adverse drug events and enhance patient adherence to treatment\u2014is generally lacking in routine clinical settings. Furthermore, the assessment of individual therapy adherence, a crucial predictive factor for therapeutic outcomes, is frequently suboptimal. In response to these issues, this study implemented an interdisciplinary approach wherein a team comprising medical and pharmaceutical professionals conducted a comprehensive survey coupled with a medication review for patients attending an IBD outpatient clinic. Employing an IBD-specific questionnaire alongside the patients\u2019 documented medication regimens enabled the identification and subsequent discussion of current therapeutic concerns and potential medication-related risks during follow-up consultations. This intervention aimed to bolster individual patient satisfaction and enhance medication safety, ultimately fostering sustained success in IBD management.<\/jats:p>","DOI":"10.3389\/fmed.2025.1446695","type":"journal-article","created":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T01:59:30Z","timestamp":1738115970000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Interprofessional approach to personalized medication management and therapy optimization in IBD care"],"prefix":"10.3389","volume":"12","author":[{"given":"Daniel","family":"Fleischmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedicta","family":"Binder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muriel","family":"Huss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Elger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Loibl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hauke Christian","family":"Tews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne","family":"Kandulski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Kratzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,29]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.3390\/jcm8111970","article-title":"History of inflammatory bowel diseases","volume":"8","author":"Actis","year":"2019","journal-title":"J Clin Med"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","article-title":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies","volume":"390","author":"Ng","year":"2017","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S2468-1253(19)30333-4","article-title":"The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990\u20132017: a systematic analysis for the global burden of disease study 2017","volume":"5","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/nrgastro.2015.34","article-title":"Epidemiology and risk factors for IBD","volume":"12","author":"Ananthakrishnan","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"105550","DOI":"10.1016\/j.ejps.2020.105550","article-title":"Recent advances in inflammatory bowel disease therapy","volume":"155","author":"Binienda","year":"2020","journal-title":"Eur J Pharm Sci"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cytogfr.2023.07.001","article-title":"Recent advances in the treatment of IBD: targets, mechanisms and related therapies","author":"Liu","year":"2023","journal-title":"Cytokine Growth Factor Rev"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"722","DOI":"10.2174\/1389450118666170502142939","article-title":"Personalizing psychological treatment along the IBD journey: from diagnosis to surgery","volume":"19","author":"Menichetti","year":"2028","journal-title":"Curr Drug Targets"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"714057","DOI":"10.3389\/fpsyt.2021.714057","article-title":"Depression and anxiety disorders in patients with inflammatory bowel disease","volume":"12","author":"Hu","year":"2021","journal-title":"Front Psych"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"104501","DOI":"10.1016\/j.psyneuen.2019.104501","article-title":"Stress and the brain-gut axis in functional and chronic-inflammatory gastrointestinal diseases: a transdisciplinary challenge","volume":"111","author":"Labanski","year":"2020","journal-title":"Psychoneuroendocrinology"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1080\/00365521.2022.2078667","article-title":"Use of complementary and alternative medicine (CAM) in patients with inflammatory bowel disease (IBD): results from a German nationwide survey of 2019 compared to a previous survey of 2002","volume":"57","author":"Bauer","year":"2022","journal-title":"Scand J Gastroenterol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.crohns.2009.11.011","article-title":"Association of adherence to therapy and complementary and alternative medicine use with demographic factors and disease phenotype in patients with inflammatory bowel disease","volume":"4","author":"Lakatos","year":"2010","journal-title":"J Crohns Colitis"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"e189","DOI":"10.1097\/MCG.0000000000001647","article-title":"Polypharmacy in patients with inflammatory bowel disease: prevalence and outcomes in a single-center series","volume":"56","author":"Mesonero","year":"2022","journal-title":"J Clin Gastroenterol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.3390\/antibiotics12121730","article-title":"Interprofessional therapeutic drug monitoring of carbapenems improves ICU care and guideline adherence in acute-on-chronic liver failure","volume":"12","author":"Schmid","year":"2023","journal-title":"Antibiotics"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1001\/jamainternmed.2020.9285","article-title":"Effect of a multifaceted clinical pharmacist intervention on medication safety after hospitalization in persons prescribed high-risk medications. A randomized clinical trial","volume":"181","author":"Gurwitz","year":"2021","journal-title":"JAMA Intern Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/imj.15504","article-title":"Pharmacists reducing medication risk in medical outpatient clinics: a retrospective study of 18 clinic","volume":"53","author":"Snoswell","year":"2021","journal-title":"Intern Med J"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.pec.2021.10.017","article-title":"Interventions to improve medication adherence in inflammatory bowel disease: a systematic review","volume":"105","author":"Gohil","year":"2020","journal-title":"Patient Educ Couns"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"434","DOI":"10.5217\/ir.2017.15.4.434","article-title":"Medication adherence in inflammatory bowel disease","volume":"15","author":"Chan","year":"2017","journal-title":"Intest Res"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/ajg.2009.685","article-title":"Factors associated with non-adherence to oral medication for inflammatory bowel disease: a systematic review","volume":"105","author":"Jackson","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.gastrohep.2019.10.007","article-title":"Survey of adherence to treatment in inflammatory bowel disease. ENADEII study","volume":"43","author":"Alonso-Abreu","year":"2020","journal-title":"Gastroenterol Hepatol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1007\/s00120-023-02225-y","article-title":"Interprofessional teamwork: the Regensburg model","volume":"62","author":"Mahnke","year":"2023","journal-title":"IUrologie"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.1055\/s-0041-1740766","article-title":"Interprofessionelle Ausbildungsstation Regensburg (A-STAR) mit gastroenterologisch-hepatologischem Schwerpunkt \u2013 Versorgungsqualit\u00e4t aus Sicht der Patienten","volume":"60","author":"Schlosser","year":"2022","journal-title":"Z Gastroenterol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.crohns.2012.09.003","article-title":"Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis","volume":"6","author":"Dignass","year":"2012","journal-title":"J Crohns Colitis"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.crohns.2009.12.002","article-title":"The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management","volume":"4","author":"Dignass","year":"2010","journal-title":"J Crohns Colitis"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1111\/j.1751-7117.2000.tb00211.x","article-title":"Development and testing of the Hill-Bone compliance to high blood pressure therapy scale","volume":"15","author":"Kim","year":"2000","journal-title":"Prog Cardiovasc Nurs"},{"key":"ref25","author":"Bacchus","year":""},{"key":"ref26","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/S0022-3999(99)00057-4","article-title":"Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness","volume":"47","author":"Horne","year":"1999","journal-title":"J Psychosom Res"},{"key":"ref27","first-page":"55","article-title":"A technique for the measurement of attitudes","volume":"22","author":"Likert","year":"1931","journal-title":"Arch Psychol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1111\/j.1365-2710.2011.01281.x","article-title":"Development of a classification system for drug-related problems in the hospital setting (APS-Doc) and assessment of the inter-rater reliability","volume":"37","author":"Hohmann","year":"2011","journal-title":"J Clin Pharm Ther"},{"key":"ref29","article-title":"A glossary of terms for community health care and services for older persons","year":"2004"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s12877-017-0621-2","article-title":"What is polymedication? A systematic review of definitions","volume":"17","author":"Masnoon","year":"2017","journal-title":"BMC Geriatr"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"e036158","DOI":"10.1136\/bmjopen-2019-036158","article-title":"Medication-related experiences of patients with polypharmacy: a systematic review of qualitative studies","volume":"10","author":"Eriksen","year":"2020","journal-title":"BMJ Open"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"izae 197","DOI":"10.1093\/ibd\/izae197","article-title":"A study of patient concerns in the modern therapeutic era of inflammatory bowel disease","author":"Gsenger","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1097\/MEG.0000000000000704","article-title":"Inflammatory bowel disease: adherence to immunomodulators in a biological therapy era","volume":"28","author":"Campos","year":"2016","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1002\/ibd.20462","article-title":"Which patients with IBD need psychological interventions? A controlled study","volume":"14","author":"Miehsler","year":"2008","journal-title":"Inflamm Bowel Dis"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1055\/a-2309-6123","article-title":"Aktualisierte S3-Leitlinie \u201cDiagnostik und Therapie des Morbus Crohn\u201d der Deutschen Gesellschaft f\u00fcr Gastroenterologie, Verdauungs-und Stoffwechselkrankheiten (DGVS) (Version 4.1) \u2013 living guideline","volume":"62","author":"Sturm","year":"2024","journal-title":"Z Gastroenterol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ecco-jcc\/jjad108","article-title":"ECCO guidelines on extraintestinal manifestations in inflammatory bowel disease","volume":"18","author":"Gordon","year":"2024","journal-title":"J Crohns Colitis"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1080\/00365521.2016.1195870","article-title":"Adherence and quality of care in IBD","volume":"51","author":"Bager","year":"2016","journal-title":"Scand J Gastroenterol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izae127","article-title":"Integrating the patient perspective to validate a measure of disease severity in inflammatory bowel disease: online survey of patients and their physicians","author":"Timmer","year":"2024","journal-title":"Inflamm Bowel Dis"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1446695\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T01:59:34Z","timestamp":1738115974000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1446695\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,29]]},"references-count":38,"alternative-id":["10.3389\/fmed.2025.1446695"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1446695","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,29]]},"article-number":"1446695"}}